Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
367 stopped studies mapped to Head and Neck Carcinoma and descendants · 94% state a reason
Over the 367 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05814666 | Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC(PEMDA-HN) | Phase 2 | terminated | Apr 18, 2023 | Flamingo Therapeutics NV | Interim analysis was negative | Efficacy / futility |
| NCT05014698 | IDEntification of New Predisposition Genes in Differentiated THYroid Cancer(IDENTHY-K) | N/A | terminated | Aug 20, 2021 | Nantes University Hospital | end-of-study visit not completed within the protocol timeframe | Other (stated, no rule matched) |
| NCT04862455 | NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic… | Phase 2 | terminated | Apr 28, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT06322576 | 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma | Phase 2 | terminated | Mar 21, 2024 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor is no longer producing the study drug, so it was not possible to complete the study. | Other (stated, no rule matched) |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04801472 | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients…(OPPIDOM) | N/A | terminated | Mar 17, 2021 | Institut de cancérologie Strasbourg Europe | organisationnal reason | Other (stated, no rule matched) |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or… | N/A | withdrawn | Sep 19, 2024 | Duke University | Changing priorities of portfolio | Sponsor / business decision |
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3… | Phase 1 / Phase 2 | withdrawn | Dec 30, 2022 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell…(HN1901) | Phase 2 | terminated | Jun 24, 2020 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | unmet primary endpoint | Other (stated, no rule matched) |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage… | Early Phase 1 | withdrawn | May 6, 2023 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04854499 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell…(ELEVATE HNSCC) | Phase 2 | terminated | Apr 22, 2021 | Gilead Sciences | Sponsor decision to terminate study | Sponsor / business decision |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT06046482 | Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for… | Phase 2 | terminated | Sep 21, 2023 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04459715 | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and… | Phase 3 | terminated | Jul 7, 2020 | EMD Serono Research & Development Institute, Inc. | Study has crossed the pre-defined futility boundary at the Interim Analysis. | Efficacy / futility |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual… | Phase 3 | terminated | Jul 7, 2020 | National Cancer Institute (NCI) | External information | Other (stated, no rule matched) |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected… | Phase 1 | terminated | Jun 27, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT05061420 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of… | Phase 2 | terminated | Sep 29, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Phase 1 | terminated | Feb 21, 2024 | Ikena Oncology | Limited resources and strategic priorities | Sponsor / business decision |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT06338657 | FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer | Phase 1 | terminated | Mar 29, 2024 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT04989387 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Aug 4, 2021 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
| NCT02363400 | A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA | Phase 3 | terminated | Feb 16, 2015 | National Health Research Institutes, Taiwan | Recruiting progress behind expectation | Enrollment / accrual |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | — | withdrawn | Apr 12, 2024 | Wake Forest University Health Sciences | PI not moving forward with study at our institution | Other (stated, no rule matched) |
| NCT02892201 | Pembrolizumab in HNSCC With Residual Disease After Radiation | Phase 2 | terminated | Sep 8, 2016 | Yale University | Low enrollment | Enrollment / accrual |
| NCT06086925 | A Window of Opportunity Study of Black Raspberry for Patients With HNSCC | Early Phase 1 | withdrawn | Oct 17, 2023 | Mitchell Machtay | The study was not initiated due to funding constraints and will not proceed in its current design. | Funding |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05879484 | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative… | Phase 1 / Phase 2 | withdrawn | May 30, 2023 | National Cancer Institute (NCI) | Study was never opened for enrollment as the CRADA was never executed | Enrollment / accrual |
| NCT03440437 | A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | Phase 1 / Phase 2 | terminated | Feb 22, 2018 | invoX Pharma Limited | Business Decision | Sponsor / business decision |
| NCT03469011 | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid… | Phase 1 | terminated | Mar 19, 2018 | AHS Cancer Control Alberta | Lack of Accrual | Enrollment / accrual |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | Formation Biologics | lack of efficacy | Efficacy / futility |
| NCT01720563 | A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell… | Phase 2 | terminated | Nov 2, 2012 | PhytoHealth Corporation | Change study drug dosage form | Other (stated, no rule matched) |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | — | withdrawn | Jul 10, 2024 | Mayo Clinic | Resident working with study left institution | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT05536037 | Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions | Phase 1 | terminated | Sep 10, 2022 | Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT04633278 | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head… | Phase 2 | terminated | Nov 18, 2020 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT05930938 | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients…(XXL_2022-01) | Phase 3 | terminated | Jul 5, 2023 | Groupe Oncologie Radiotherapie Tete et Cou | toxicity | Safety / toxicity |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT03053960 | Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in… | — | terminated | Feb 15, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated by IRB | Other (stated, no rule matched) |
| NCT04595981 | Chemo-embolization for Head and Neck Cancer | Phase 2 | withdrawn | Oct 22, 2020 | University of Alabama at Birmingham | No staff or funding to do the study. | Funding |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT05322135 | A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma | Early Phase 1 | terminated | Apr 11, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 30, 2026source: clinicaltrials